Influence of anti-TNF therapy on bone metabolism in patients with inflammatory bowel disease

Published: 4 February 2017
Author(s): Beatriz Castro, Montserrat Rivero, Javier Crespo, J. Antonio Riancho, Carmen Valero
Section: Letter to the Editor

Several studies conclude that patients with inflammatory bowel disease (IBD) are at an increased risk of osteoporosis (30–50%) [1] and fractures (1.3 to 2.5 times) [2]. Different factors can be implicated (intestinal malabsorption, hypogonadism, physical inactivity, use of corticoids and deficiency of vitamin D) [3,4]. Moreover, the increase of proinflammatory cytokines, such as the tumor necrosis factor (TNF) and the interleukins (IL), also appear to be involved in the pathogenesis of bone loss in these patients [5].